Study S001579

GLP-1R Agonist Treatment for Opioid Use Disorder

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06548490
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 200
Start: 2025-01-27
Primary completion: 2027-04-30
Lead sponsor: Milton S. Hershey Medical Center
Conditions: Opioid Use Disorder; Opioid Abuse and Addiction; Narcotic-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorder; Opioid
Interventions: DRUG:Semaglutide Pen Injector; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: NIH:UH3DA050325

Registered primary outcomes

Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 2]
Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 3]
Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 4]
Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 5]
Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 6]
Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 7]
Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 8]
Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 9]
Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 10]
Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 11]
Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 12]
Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 13]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0001950	Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol. Freet CS, Addiction science & clinical practice	2025	Protocol	PMID 41168808 DOI	cites ClinicalTrials.gov:NCT06548490; registry reference DERIVED:41168808
R0002840	Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocol. Freet CS, Research square	2025	Protocol	PMID 40502777 DOI	cites ClinicalTrials.gov:NCT06548490; registry reference DERIVED:40502777